Clinical efulness of Measurement of Serum Fructosamine in Diabetics: Influence of Renal Failure, Liver Cirrhosis, and Thyroid Dysfunction

Yasuhiro Sako, Fumio Umeda, Toshihiko Hashimoto, Toyoshi Inoguchi, Kazuo Mimura, Makoto Kunisaki, Yuji Tajiri, Hidehiro Ishii, Tsukasa Yamashita, Teruaki Yamauchi, Hajime Nawata

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Measurement of serum fructosamine (FRA) by means of a Roche kit is a simple and reliable method for estimating glycosylated serum proteins. The level of FRA can be affected by hyperglycemia in diabetics and an abnormal metabolic state of serum proteins such as albumin in patients with renal failure, liver cirrhosis, and thyroid dysfunction. We measured FRA in diabetics and these patients. The average FRA level was 2.58 ± 0.08 (mean ± SE) mmol/l in the normal controls (n=18), 4.60±0.67 in patients with IDDM (n=8), and 3.61±0.10 in patients with NIDDM (n=63). In the patients with non-diabetic renal failure, while the FRA level was significantly (p<0.05) low, FRA corrected by total protein concentration was not different from that of the normal controls. The FRA level in liver cirrhosis without hyperbilirubinemia was not significantly different from that of normal controls. In the patients with thyroid disease, the FRA level was 2.08±0.03 in hyperthyroidism and 3. 11 ±0.07 in hypothyroidism. Moreover, the FRA level was negatively correlated with the thyroid hormones T 3 and T 4 (p<0.001). It is concluded that measurement of FRA is clinically useful for evaluating short-term glycemic control in diabetics even when there is complicating nephropathy or liver cirrhosis. However, its level in diabetic patients with hyperbilirubinemia or thyroid dysfunction must be cautiously interpreted.

    Original languageEnglish
    Pages (from-to)929-935
    Number of pages7
    JournalJournal of the Japan Diabetes Society
    Volume31
    Issue number12
    DOIs
    Publication statusPublished - Jan 1 1988

    Fingerprint

    Fructosamine
    Liver Cirrhosis
    Renal Insufficiency
    Thyroid Gland
    Serum
    Hyperbilirubinemia
    Thyroid Diseases
    Hyperthyroidism
    Hypothyroidism
    Type 1 Diabetes Mellitus
    Thyroid Hormones
    Hyperglycemia
    Type 2 Diabetes Mellitus
    Blood Proteins
    Albumins

    All Science Journal Classification (ASJC) codes

    • Internal Medicine
    • Endocrinology, Diabetes and Metabolism
    • Endocrinology

    Cite this

    Clinical efulness of Measurement of Serum Fructosamine in Diabetics : Influence of Renal Failure, Liver Cirrhosis, and Thyroid Dysfunction. / Sako, Yasuhiro; Umeda, Fumio; Hashimoto, Toshihiko; Inoguchi, Toyoshi; Mimura, Kazuo; Kunisaki, Makoto; Tajiri, Yuji; Ishii, Hidehiro; Yamashita, Tsukasa; Yamauchi, Teruaki; Nawata, Hajime.

    In: Journal of the Japan Diabetes Society, Vol. 31, No. 12, 01.01.1988, p. 929-935.

    Research output: Contribution to journalArticle

    Sako, Y, Umeda, F, Hashimoto, T, Inoguchi, T, Mimura, K, Kunisaki, M, Tajiri, Y, Ishii, H, Yamashita, T, Yamauchi, T & Nawata, H 1988, 'Clinical efulness of Measurement of Serum Fructosamine in Diabetics: Influence of Renal Failure, Liver Cirrhosis, and Thyroid Dysfunction', Journal of the Japan Diabetes Society, vol. 31, no. 12, pp. 929-935. https://doi.org/10.11213/tonyobyo1958.31.929
    Sako, Yasuhiro ; Umeda, Fumio ; Hashimoto, Toshihiko ; Inoguchi, Toyoshi ; Mimura, Kazuo ; Kunisaki, Makoto ; Tajiri, Yuji ; Ishii, Hidehiro ; Yamashita, Tsukasa ; Yamauchi, Teruaki ; Nawata, Hajime. / Clinical efulness of Measurement of Serum Fructosamine in Diabetics : Influence of Renal Failure, Liver Cirrhosis, and Thyroid Dysfunction. In: Journal of the Japan Diabetes Society. 1988 ; Vol. 31, No. 12. pp. 929-935.
    @article{7cf32b840e2d44d38e1fd3a7795e471c,
    title = "Clinical efulness of Measurement of Serum Fructosamine in Diabetics: Influence of Renal Failure, Liver Cirrhosis, and Thyroid Dysfunction",
    abstract = "Measurement of serum fructosamine (FRA) by means of a Roche kit is a simple and reliable method for estimating glycosylated serum proteins. The level of FRA can be affected by hyperglycemia in diabetics and an abnormal metabolic state of serum proteins such as albumin in patients with renal failure, liver cirrhosis, and thyroid dysfunction. We measured FRA in diabetics and these patients. The average FRA level was 2.58 ± 0.08 (mean ± SE) mmol/l in the normal controls (n=18), 4.60±0.67 in patients with IDDM (n=8), and 3.61±0.10 in patients with NIDDM (n=63). In the patients with non-diabetic renal failure, while the FRA level was significantly (p<0.05) low, FRA corrected by total protein concentration was not different from that of the normal controls. The FRA level in liver cirrhosis without hyperbilirubinemia was not significantly different from that of normal controls. In the patients with thyroid disease, the FRA level was 2.08±0.03 in hyperthyroidism and 3. 11 ±0.07 in hypothyroidism. Moreover, the FRA level was negatively correlated with the thyroid hormones T 3 and T 4 (p<0.001). It is concluded that measurement of FRA is clinically useful for evaluating short-term glycemic control in diabetics even when there is complicating nephropathy or liver cirrhosis. However, its level in diabetic patients with hyperbilirubinemia or thyroid dysfunction must be cautiously interpreted.",
    author = "Yasuhiro Sako and Fumio Umeda and Toshihiko Hashimoto and Toyoshi Inoguchi and Kazuo Mimura and Makoto Kunisaki and Yuji Tajiri and Hidehiro Ishii and Tsukasa Yamashita and Teruaki Yamauchi and Hajime Nawata",
    year = "1988",
    month = "1",
    day = "1",
    doi = "10.11213/tonyobyo1958.31.929",
    language = "English",
    volume = "31",
    pages = "929--935",
    journal = "Journal of the Japan Diabetes Society",
    issn = "0021-437X",
    publisher = "Japan Diabetes Society",
    number = "12",

    }

    TY - JOUR

    T1 - Clinical efulness of Measurement of Serum Fructosamine in Diabetics

    T2 - Influence of Renal Failure, Liver Cirrhosis, and Thyroid Dysfunction

    AU - Sako, Yasuhiro

    AU - Umeda, Fumio

    AU - Hashimoto, Toshihiko

    AU - Inoguchi, Toyoshi

    AU - Mimura, Kazuo

    AU - Kunisaki, Makoto

    AU - Tajiri, Yuji

    AU - Ishii, Hidehiro

    AU - Yamashita, Tsukasa

    AU - Yamauchi, Teruaki

    AU - Nawata, Hajime

    PY - 1988/1/1

    Y1 - 1988/1/1

    N2 - Measurement of serum fructosamine (FRA) by means of a Roche kit is a simple and reliable method for estimating glycosylated serum proteins. The level of FRA can be affected by hyperglycemia in diabetics and an abnormal metabolic state of serum proteins such as albumin in patients with renal failure, liver cirrhosis, and thyroid dysfunction. We measured FRA in diabetics and these patients. The average FRA level was 2.58 ± 0.08 (mean ± SE) mmol/l in the normal controls (n=18), 4.60±0.67 in patients with IDDM (n=8), and 3.61±0.10 in patients with NIDDM (n=63). In the patients with non-diabetic renal failure, while the FRA level was significantly (p<0.05) low, FRA corrected by total protein concentration was not different from that of the normal controls. The FRA level in liver cirrhosis without hyperbilirubinemia was not significantly different from that of normal controls. In the patients with thyroid disease, the FRA level was 2.08±0.03 in hyperthyroidism and 3. 11 ±0.07 in hypothyroidism. Moreover, the FRA level was negatively correlated with the thyroid hormones T 3 and T 4 (p<0.001). It is concluded that measurement of FRA is clinically useful for evaluating short-term glycemic control in diabetics even when there is complicating nephropathy or liver cirrhosis. However, its level in diabetic patients with hyperbilirubinemia or thyroid dysfunction must be cautiously interpreted.

    AB - Measurement of serum fructosamine (FRA) by means of a Roche kit is a simple and reliable method for estimating glycosylated serum proteins. The level of FRA can be affected by hyperglycemia in diabetics and an abnormal metabolic state of serum proteins such as albumin in patients with renal failure, liver cirrhosis, and thyroid dysfunction. We measured FRA in diabetics and these patients. The average FRA level was 2.58 ± 0.08 (mean ± SE) mmol/l in the normal controls (n=18), 4.60±0.67 in patients with IDDM (n=8), and 3.61±0.10 in patients with NIDDM (n=63). In the patients with non-diabetic renal failure, while the FRA level was significantly (p<0.05) low, FRA corrected by total protein concentration was not different from that of the normal controls. The FRA level in liver cirrhosis without hyperbilirubinemia was not significantly different from that of normal controls. In the patients with thyroid disease, the FRA level was 2.08±0.03 in hyperthyroidism and 3. 11 ±0.07 in hypothyroidism. Moreover, the FRA level was negatively correlated with the thyroid hormones T 3 and T 4 (p<0.001). It is concluded that measurement of FRA is clinically useful for evaluating short-term glycemic control in diabetics even when there is complicating nephropathy or liver cirrhosis. However, its level in diabetic patients with hyperbilirubinemia or thyroid dysfunction must be cautiously interpreted.

    UR - http://www.scopus.com/inward/record.url?scp=85007978583&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85007978583&partnerID=8YFLogxK

    U2 - 10.11213/tonyobyo1958.31.929

    DO - 10.11213/tonyobyo1958.31.929

    M3 - Article

    AN - SCOPUS:85007978583

    VL - 31

    SP - 929

    EP - 935

    JO - Journal of the Japan Diabetes Society

    JF - Journal of the Japan Diabetes Society

    SN - 0021-437X

    IS - 12

    ER -